Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Onyx, Bayer Phase II RCC data

ONXX and partner Bayer (FSE:BAYG; BAY) said interim results from a Phase II study in patients with

Read the full 174 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE